We hypothesized that the prevalence of constipation amongst children on chemotherapy would be high, and that certain pharmacologic interventions commonly used in this population (especially vinca alkaloids, narcotic analgesics, and ondansetron) would be associated with constipation. We also hypothesized that constipation would be perceived as an important problem with a significant impact on lifestyle. We prospectively studied 61 children receiving chemotherapy for cancer by administering questionnaires to patients and their parents. We obtained demographics, bowel movement history, interventions for constipation, chemotherapy agents, other medications, perception of constipation as a problem, and impact on lifestyle. 35 of 61 (57% ± 12%) children were found to meet NASPGHAN criteria for constipation during chemotherapy, while 46 of 61 (77% ± 11%) were found to have signs and symptoms suggestive of constipation and 42 of 61 (69% ± 12%) required the use of laxatives while on chemotherapy. Among children with NASPGHAN criteria constipation, 15 of 35 (43% ± 16%) perceived it as a major/significant problem and 8 of 35 (23% ± 14%) noted a major/significant impact on lifestyle. We concluded that criteria for acute constipation were found in 57% of children receiving chemotherapy for cancer, though less stringent criteria suggest a prevalence of up to 77%. Even though this study lacked sufficient power for most associations, combined use of vincristine and opiates was associated with constipation (p<0.03). Constipation was found to have a high prevalence in children on chemotherapy, and it is perceived as a significant problem by patients and their parents with an adverse effect on lifestyle. 
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Introduction and Background
Constipation is a common problem in the pediatric population in general, however it is particularly common in children receiving chemotherapy for cancer (1) . This common chemotherapy-associated adverse effect is well known to pediatric oncologists; a 2005 survey of 12 pediatric oncology units (54% response rate) in the United Kingdom demonstrated that 100% perceived constipation as a problem within their patient group, an observation which has been echoed by pediatric oncologists at Yale-New Haven Hospital and at Children's Hospital in Leeds, United Kingdom (1) (2) (3) . Despite this high awareness, there is no published research focused on constipation in the pediatric oncology population (other than that which was published based on this thesis) (2) .
A 2008 systematic review of treatments for constipation in children and young adults undergoing chemotherapy reviewed 1336 abstracts and failed to find even a single article which was suitable for inclusion, as none included pediatric patients (3) . As far as we are aware, no prior study had yet tried to assess either the extent or the impact of constipation in this population, both of which might currently be underappreciated by clinicians.
We therefore planned a prospective study to evaluate the prevalence of constipation in children undergoing chemotherapy in New
Haven county using an in-person interview and questionnaire. We also tried to assess perceptions of patients and family members about the degree to which constipation was a problem and its impact on quality of life, while also investigating likely risk factors for constipation and treatment strategies used to treat bouts of constipation. For the purposes of this study, we defined constipation according to the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) criteria because, which defines constipation as delay or difficulty in defecation for 2 or more weeks (45) .
Constipation, in the general pediatric population, has a significant healthcare impact. It accounts for 3-10% of visits to general pediatric practitioners and up to 25% of referrals to pediatric gastroenterologists worldwide (4) (5) (6) . Studies on the worldwide prevalence of functional constipation have found that the rate varies from 0.7% to 29.6% and is common in all pediatric age ranges, from infants to young adults (7, 8) .
Given this high prevalence, constipation is associated with high healthcare expenditures. Costs per individual are also significant, especially as constipated children have been shown to have more visits to outpatient clinics and emergency departments and more inpatient admissions than matched controls (9) . A 2006 prospective study calculated the mean annual expenditure for treatment of chronic constipation to be $7,522 per patient, with an average diagnostic study cost of nearly $3,000 per patient (10) . While a 1993 British study found that GBP£43 million is spent annually on prescription laxatives, and an analysis of three United States surveys estimated the total health-related cost of adult constipation to be US$235 million in 2001, pediatric constipation in the United States has been estimated using the Medical Expenditure
Panel Survey database to cost US$3.9 billion per year (11) (12) (13) .
Stooling frequency and bowel habits reflect a pronounced interindividual variation which makes defining "normal" a frustrating task, however the bounds of normal habits can be loosely defined with regards to age. A 1989 study used diary recordings to characterize the bowel habits of 662 children in Italy. Starting at age three, most children will have between three stools per week to three stools per day, and by age 5
to age 8 most children will have settled into a more consistent mediumsized bowel movement, either daily or every other day, without straining or exhibiting withholding behavior (14, 15) .
Dealing with constipation, however, presents a challenge as the term has many different meanings to different people, from children, to parents, to physicians and researchers (16) . To patients it can mean the need for excessive straining, hard stools, infrequent stools, infrequent defecation, the inability to defecate when desired, abdominal pain or discomfort, or the sensation of an incompletely evacuated bowel (17) .
Given the nonspecific nature of these symptoms, many of them will be experienced in the absence of any pathology; indeed, a 2011 study showed that 20% of 10 to 16-year-olds have at least 1 clinical feature of constipation (18) . As a result, physicians have attempted several times to define more specific criteria for the constipation. Constipation has been traditionally defined as less than 3 bowel movements per week, however patient self-reports of bowel frequency have been shown to be inaccurate and poorly correlated with other signs and symptoms of constipation (19). In 1999, gastroenterology clinicians put forward the Rome II criteria for functional constipation based largely on expert opinion, criteria which were soon found to be too restrictive and thus insensitive for constipation (16) . These standards were then revised and broadened between 2004 and 2006, and they define constipation as having at least two of the following at least weekly for at least 2 months (without evidence of an organic disease which could be causing them): 2 or fewer bowel movements in the toilet per week, episodes of fecal incontinence in children > 4 years of age, history of retentive posturing or excessive volitional stool retention, history of painful or hard bowel movements, history of large diameter stools which may obstruct the toilet, or the presence of a large fecal mass in the abdomen or rectum (20) .
Infants can also be diagnosed with a similar functional disorder, infant dyschezia, if an otherwise healthy infant less than 6 months of age endures 10 minutes of straining and crying before passing soft stools. The changes in the Rome III criteria resulted in a 42% jump in children being diagnosed with functional constipation (21) . Alternatively, as the Rome III criteria still sacrifice sensitivity for specificity by having more stringent criteria and longer duration requirements, the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) offer
an alternate and less restrictive definition of constipation as delay or difficulty in defecation for 2 or more weeks (45) .
For many children, constipation is triggered by the occurrence of painful bowel movements, often the result of toilet training, delaying defecation, changes in routine, changes in diet, stressful events, or illness (22) . Peak incidence occurs at about the time of toilet training (8) . As feces are retained within the colon, more water is reabsorbed over time, and stools become harder and more difficult to pass, and defecation becomes more painful. This can cause the accumulation of hard stool in the rectal vault and the onset of fecal impaction (22) . It can also lead to overflow fecal incontinence or loss of the normal urge to defecate (16) .
Some children with chronic constipation have also been found to have reduced rectal sensation, increased rectal wall compliance, or both. This can manifest itself as megarectum, though it is unknown whether these sensorimotor dysfunctions are primary or secondary to constipation (16, 23) .
Suggested risk factors for constipation include genetics (a family history of constipation), low consumption of fiber (which functions as an osmotic laxative and a mechanical stimulator of colonic motility), low levels of physical activity, obesity, living in a high-population-density community and low parent education levels (7, 24) . Constipation has also been associated with behavioral problems, though cause and effect can be difficult to discern as constipation can be both a source and a manifestation of behavioral problems (25 (27) .
In the adult population, various chemotherapy agents have already been strongly associated with constipation. Patients receiving vinca alkaloids (vincristine/vinblastine) have been shown to experience constipation at a rate of up to 35%, while for carboplatin one study demonstrated a constipation rate of 70% (27, 33) . Constipation has also been strongly linked to opiates and the antiemetic ondansetron (34) (35) (36) .
The constipating effects of ondansetron are, in particular, most often overlooked as they are less well known to be a side effect. Furthermore, nurses may be more focused on monitoring antiemetic effects than side effects, and constipation may be seen as a worthy trade-off to relieve nausea (27, 37) .
Importantly, some of the adult literature emphasizes the importance of prophylactic treatment with laxatives before the onset of constipation.
As Smith put it in the opening of his review on constipation in the oncology patient, "A need to treat constipation is often due to a failure to prevent it" (27) . In one study which tracked ten newly-diagnosed osteosarcoma patients entering treatment, six were admitted for reasons related to constipation, and four developed systemic infections from an anal fissure or abscess (27) . Authors have noted that intervention is often delayed until a significant problem sets in, and that this is likely due to a lack of consensus on treatment protocols (27, 38) . Significantly, protocols for prophylaxis do exist for morphine, codeine, vinca alkaloids, and ondansetron (27) . The need for similar prophylactic protocols has been proposed for children on chemotherapy as well (1).
While no data exists in the pediatric oncology literature regarding constipation, many studies have been done regarding prophylaxis and treatment of nausea and vomiting for children (2) . One such study was a double-blind, crossover, randomized study evaluating the safety and efficacy of two doses of granisetron for the prophylactic prevention of nausea when receiving emetogenic doses of carboplatin (39) . As Berrak notes in that study, "Without effective prophylaxis, severe and protracted nausea and vomiting may result in dehydration, electrolyte imbalance, malnutrition, aspiration pneumonia, and increased hospitalization rates (40) . Furthermore, these symptoms may be so distressing that the patients' quality of life can be affected, leading to the discontinuation of life-saving medications (41) . Therefore, effective and well-tolerated antiemetic therapy is vital for patients receiving intensive chemotherapy." A very similar argument could be made for constipation.
As we could find no data on constipation in children receiving chemotherapy for cancer, we designed a prospective survey study to establish the prevalence of constipation in this population. We also studied the prevalence of suspected risk factors for constipation in this group, the association of certain chemotherapy agents and drugs to constipation, and the degree to which constipation was perceived as a problem with an impact on the lives of patients and their families. We also We hypothesized that the prevalence of constipation amongst children on chemotherapy would be high, and that certain pharmacologic interventions commonly used in this population (especially vinca alkaloids, narcotic analgesics, and ondansetron) would be associated with constipation. We also hypothesized that constipation would be perceived as an important problem with a significant impact on lifestyle.
The specific aims of this study were to 1) determine the prevalence of constipation in children on chemotherapy, 2) assess the association of constipation on a scale of 0-3, with 0 indicating "not a problem," 1 a "minor problem," 2 a "significant problem," or 3 a "major problem." They were also asked to rate the impact of constipation on their lifestyle also on a scale of 0-3, with 0 being "no impact," 1 being "mild," 2 being "significant," or 3 being "severe impact."
Statistical analysis of the association of various parameters with constipation was assessed using the Fisher exact test using a 2x2 contingency 
Results
We were able to recruit sixty-one children to participate in this study. Information regarding their demographic information, cancer diagnosis, chemotherapy agents received, and opiate use are included in Table 1 . No children were diagnosed with a gastrointestinal tract malignancy, and two children were subjected to abdominal radiation alongside their chemotherapy. In addition to the chemotherapy agents listed, other chemotherapy agents included cyclophosphamide (n=13), doxorubicin (n=11), daunorubicin (n=6), bleomycin (n=6), etoposide (n=6), vinblastine (n=4), carboplatin (n=3), dacarbazine (n=3), temozolomide (n=2), actinomysin (n=2), gleomycin (n=2), and alpha-interferon (n=1).
Besides chemotherapy, other commonly used medications included ondansetron (n=33), diphenhydramine (n=11), and acid suppression therapy (n=23) which included famotidine, ranitidine, and lansoprazole. 8 children underwent surgery for tumor resection, while 2 children had a history of inguinal hernia repair. 
Laxative Use

Numbers Laxative Use
The one ineffective regimen which included PEG 3350 was a regimen of a standing dose of oral docusate with PEG 3350 used on an as needed basis. This was changed to a regimen of a standing dose of PEG 3350, which was effective. Other regimens were discontinued due to failure of the patient to tolerate the laxative medication, due to either taste or the size of the medication pill. These are also summarized in table 3. Notably, 
Discussion
Of 61 children receiving chemotherapy for cancer enrolled in this study, 57% ± 12% (95% CI) were found to have experienced acute constipation, defined as delayed or difficult defecation for 2 weeks. If the 2 month time requirement of the Rome III criteria for functional constipation is set aside, the same prevalence is seen when this criteria is applied. Both of these values are significantly higher than estimations for constipation in the general pediatric population of 0.7% to 29.6%, p<0.05 (16) . However, the sensitivity of both of these instruments is demonstrably low, given that 77% ± 11% (95% CI) had some signs and symptoms which are evidence of constipation including the onset of hard or painful stools, 75% ± 11% (95% CI) noted self-described constipation within days of receiving chemotherapy, and 69% ± 12% (95% CI) required the use of a laxative regimen. Defining constipation in children has been a devilishly difficult task, one which has required experts to frequently revise their widely used consensus expert opinions several times to address concerns about low sensitivity (16, 46) . The diagnoses of our patients reflected the more common pediatric cancer diagnoses, and 90% of the patients recruited for our study had diagnoses of either acute lymphoid leukemia, non-CNS solid tumors, or lymphoma. We assessed for several risk factors for constipation in our population. For example, 12% ± 20% (95% CI) of our recruited patients were obese, which was recently shown to be a risk factor for constipation in children (47) . Obesity was not related to constipation in our study, though this study may not have been sufficiently powered to make this association should one exist. The range of patient ages recruited for our study was broad (1.1y to 20.4y), although this means that fewer patients were gathered from each age group. As 1-year-olds are certainly very different from 10-year-olds, who are in turn very different from 20-yearolds, the lower power afforded by our sample size may not have been able to resolve any differences that might be seen amongst different age groups.
This low power also restricted finding associations between constipation and certain suspect medications. While the combination of vincristine and opiates was significantly associated with an increased risk of constipation (p<0.03) and likely has a particularly strong association, no other medication associations reached statistical significance in this study.
This included isolated and combined use of vincristine, methotrexate, 6-mercaptopurine, cytosine arabinoside, and opiates. Vincristine affects the gut through the induction of gastrointestinal neuropathy, which slows gastrointestinal motility. Opiates have a similar effect by inhibiting mu receptors in the gastrointestinal nervous system, which inhibits peristalsis and also slows motility, and so the two medications may have a synergistic effect. When a child is receiving both opiates and vincristine, providers must be especially vigilant for (or prophylax for) constipation.
The importance of addressing constipation is readily apparent in the data from this study. While only 11% ± 11% (95% CI) of children with constipation by NASPGHAN criteria said that constipation was not a problem, 43% ± 16% (95% CI) identified it as a significant or major problem.
This was in families dealing with the huge distracting problem of a lifethreatening cancer diagnosis in a child and all of the side effects of chemotherapy that entails. That constipation was such a large problem to this group of people is very telling. Indeed, in children functional constipation has been shown to negatively affect quality-of-life scores more than inflammatory bowel disease (48) . 23% ± 11% (95% CI) also reported that constipation had either a significant or major effect on their lifestyle. Beyond the patient experience, if a neutropenic child develops acute abdominal pain and abdominal distention from constipation, this can easily be confused with the presentation of neutropenic enterocolitis (2) . If constipation causes an anal fissure or abscess in a neutropenic patient, this can lead to systemic infection and even death. Constipation also was shown to contribute to healthcare costs in this group, with 14 children seeking a physician's care specifically for constipation, including 9 in an outpatient setting, 3 in the emergency department, and 2 admitted to the inpatient wards.
The adult literature treats constipation in patients on chemotherapy as a failure of prevention, and this may be a useful paradigm in the pediatric population as well (27) . Of note, every child we recruited who required the use of a laxative was able to find a regimen which was effective. While our study was not designed or powered to evaluate or compare laxative regimens and is inadequate to reach definitive conclusions regarding therapy recommendations, interesting observations can be made. Firstly, a wide range of management strategies, laxative agents, and dosages was used, demonstrating high variability in approaches to constipation. This highlights the need to standardize treatments, both so that comparative studies can be carried out and because some physicians' "strongly-held, beliefs driven and self- In conclusion, the study's principle goal was achieved, supporting the hypothesis that the prevalence in constipation in children receiving chemotherapy was high, observed at 57% ± 12% (95% CI) using the NASPGHAN criteria for constipation, though the actual prevalence may be higher. This prevalence is certainly higher than previous estimates for the general pediatric population. Constipation is significantly associated with the combination of vincristine and opiates (p<0.03), even in this study of limited power. Furthermore, this constipation is seen as either a significant or major problem in 43% ± 16% of cases, with a significant or major impact on lifestyle in 23% ± 14% of cases. It is a side effect which requires greater attention, standardization of treatment, and further research into comparative laxative effectiveness in order to address this important condition.
